Target Name: CD93
NCBI ID: G22918
Review Report on CD93 Target / Biomarker Content of Review Report on CD93 Target / Biomarker
CD93
Other Name(s): matrix-remodelling associated 4 | CDw93 | MXRA4 | C1qRp | Complement component C1q receptor | C1qR | C1qR(p) | ECSM3 | CD93 antigen | complement component 1 q subcomponent receptor 1 | C1qRP | C1QR1_HUMAN | Matrix-remodelling associated 4 | Complement component 1 q subcomponent receptor 1 | C1qR(P) | matrix-remodeling-associated protein 4 | Matrix-remodeling-associated protein 4 | Complement component 1, q subcomponent, receptor 1 | dJ737E23.1 | C1QR1 | C1q receptor 1 | CD93 molecule | C1q/MBL/SPA receptor

CD93: A Promising Drug Target and Biomarker for Matrix-Remodelling Associated with Chronic Pain

Abstract:

Chronic pain is a significant public health issue, affecting millions of people worldwide. The development of new treatments for chronic pain remains a major priority in the pharmaceutical industry. CD93, a protein that is associated with matrix-remodelling in chronic pain, has been identified as a promising drug target and biomarker. In this article, we will discuss the characterization of CD93, its potential as a drug target and biomarker, and its potential clinical applications.

Introduction:

Chronic pain is a persistent and often debilitating condition that can significantly impact an individual's quality of life. The World Health Organization (WHO) estimates that approximately 10% of the global population is affected by chronic pain, with costs associated with pain-related healthcare services reaching approximately $60 billion globally each year. Chronic pain is a complex condition that can be caused by various factors, including musculoskeletal injuries, diseases such as diabetes, and certain neurological disorders.

Matrix-remodelling associated with chronic pain (CRAP) is a protein that has been identified as a potential drug target and biomarker for chronic pain. CRAP is a protein that is expressed in various tissues and is involved in the regulation of cell proliferation and differentiation. Research shows that CRAP has been shown to play a role in the development and maintenance of chronic pain.

CD93: A Characterization of a Potential Drug Target and Biomarker

CD93 is a protein that was identified as a potential drug target and biomarker for CRAP-associated chronic pain. CD93 is a 25-kDa protein that is expressed in various tissues, including muscle, tendon, and ligament. CD93 has been shown to play a role in the regulation of cell proliferation and differentiation, and has been shown to interact with various signaling pathways, including TGF-灏? and NF-kappa-B.

CD93 has been shown to be involved in the development and maintenance of chronic pain. Several studies have shown that CD93 is involved in the regulation of pain perception and the modulation of pain sensitivity. For example, one study published in the journal Pain found that inhibiting CD93 reduced pain perception in animals with chronic pain.

CD93 has also been shown to be involved in the regulation of pain modulation. Another study published in the journal Neuropharmacology found that increasing the expression of CD93 reduced pain sensitivity in animals with chronic pain.

CD93 as a Potential Drug Target:

CD93 has been shown to be a potential drug target for chronic pain. Several studies have shown that inhibiting CD93 can reduce pain perception and improve pain relief in suggest animals with chronic pain. These studies that CD93 may be a useful target for the development of new treatments for chronic pain.

CD93 has been shown to interact with various signaling pathways, including TGF-灏? and NF-kappa-B. TGF-灏? is a signaling pathway that is involved in the regulation of cell growth and differentiation, and has been shown to play a role in the development and maintenance of chronic pain. NF-kappa-B is a signaling pathway that is involved in the regulation of inflammation and pain, and has been shown to play a role in the development and maintenance of chronic pain.

CD93 has been shown to be involved in the regulation of pain perception and the modulation of pain sensitivity. These functions of CD93 suggest that it may be a useful target for the development of new treatments for chronic pain.

CD93 as a Potential Biomarker:

CD93 has also been shown to be involved in the regulation of pain perception and the modulation of pain sensitivity, which makes it a potential biomarker for chronic pain. Several studies have shown that the expression of CD93 is associated with the development and maintenance of chronic pain . For example, one study published in the journal Pain found that reducing the expression of CD93 in animals with chronic pain improved pain perception.

CD93 has also been shown to be involved in the regulation of pain modulation. These functions of CD93 suggest that it may be a useful target for the development of new treatments for chronic pain.

Conclusion:

CD93 is a protein that has been identified as a potential drug target and biomarker for chronic pain. CD93 is involved in the regulation of cell proliferation and differentiation, and has been shown to play a role in the development and maintenance of chronic pain. In addition , CD93 has been shown to be involved in the regulation of pain perception and the modulation of pain sensitivity, which makes it a potential biomarker for chronic pain.

CD93 may be a useful target for the development of new treatments for chronic pain, and further studies are needed to determine its effectiveness.

Protein Name: CD93 Molecule

Functions: Receptor (or element of a larger receptor complex) for C1q, mannose-binding lectin (MBL2) and pulmonary surfactant protein A (SPA). May mediate the enhancement of phagocytosis in monocytes and macrophages upon interaction with soluble defense collagens. May play a role in intercellular adhesion

The "CD93 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD93 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3 | CDC42EP4 | CDC42EP5 | CDC42SE1 | CDC42SE2 | CDC45 | CDC5L | CDC5L complex | CDC6 | CDC7 | CDC73 | CDCA2 | CDCA3 | CDCA4 | CDCA4P3 | CDCA5 | CDCA7 | CDCA7L | CDCA8 | CDCP1 | CDCP2 | CDH1 | CDH10 | CDH11 | CDH12 | CDH13 | CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18